UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Patch testing

Author
Bruce A Brod, MD
Section Editor
Joseph Fowler, MD
Deputy Editor
Rosamaria Corona, MD, DSc

INTRODUCTION

Patch testing is an essential investigation to identify specific allergens in allergic contact dermatitis (ACD) or, in some cases, to make the diagnosis of ACD. Patch testing is based upon the principle that in sensitized individuals, primed antigen-specific T lymphocytes of the Th1 phenotype circulate throughout the body and are able to recreate a delayed-type hypersensitivity reaction when nonirritating concentrations of the antigen are applied to normal skin.

This topic will discuss indications, techniques, and interpretation of patch testing. The basic mechanisms, clinical manifestations, diagnosis, and management of ACD are discussed separately. (See "Basic mechanisms and pathophysiology of allergic contact dermatitis" and "Clinical features and diagnosis of allergic contact dermatitis" and "Management of allergic contact dermatitis".)

INDICATIONS FOR PATCH TESTING

Indications for patch testing may include:

Persistent eczematous eruptions when contact allergy is suspected [1]

Any chronic dermatitis, especially when involving the hands, feet, face, or eyelids

                          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: May 2017. | This topic last updated: Jun 04, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Bourke J, Coulson I, English J, British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of contact dermatitis: an update. Br J Dermatol 2009; 160:946.
  2. www.acpmedicine.com (Accessed on August 06, 2009).
  3. Schalock PC, Dunnick CA, Nedorost S, et al. American Contact Dermatitis Society Core Allergen Series: 2017 Update. Dermatitis 2017; 28:141.
  4. Cohen DE, Brancaccio R, Andersen D, Belsito DV. Utility of a standard allergen series alone in the evaluation of allergic contact dermatitis: a retrospective study of 732 patients. J Am Acad Dermatol 1997; 36:914.
  5. Dooms-Goossens A. Patch testing without a kit. In: Practical contact dermatitis: A handbook for the practitioner, Guin JD (Ed), McGraw-Hill Inc., New York 1995. p.63.
  6. deGroot AC, Frosch PJ. Patch test concentrations and vehicles for testing contact allergens. In: Contact Dermatitis, 3rd ed, Frosch PJ, Menne T, Lepooittevin JP (Eds), Springer, Berlin 2006. p.907.
  7. Sukanto H, Nater JP, Bleumink E. Influence of topically applied corticosteroids on patch test reactions. Contact Dermatitis 1981; 7:180.
  8. Anveden I, Lindberg M, Andersen KE, et al. Oral prednisone suppresses allergic but not irritant patch test reactions in individuals hypersensitive to nickel. Contact Dermatitis 2004; 50:298.
  9. O'Quinn SE, Isbell KH. Influence of oral prednisone on eczematous patch test reactions. Arch Dermatol 1969; 99:380.
  10. Condie MW, Adams RM. Influence of oral prednisone on patch-test reactions to Rhus antigen. Arch Dermatol 1973; 107:540.
  11. Rosmarin D, Gottlieb AB, Asarch A, Scheinman PL. Patch-testing while on systemic immunosuppressants. Dermatitis 2009; 20:265.
  12. Wee JS, White JM, McFadden JP, White IR. Patch testing in patients treated with systemic immunosuppression and cytokine inhibitors. Contact Dermatitis 2010; 62:165.
  13. Kim N, Notik S, Gottlieb AB, Scheinman PL. Patch test results in psoriasis patients on biologics. Dermatitis 2014; 25:182.
  14. Goossens A. Recognizing and testing allergens. Dermatol Clin 2009; 27:219.
  15. Goossens A. Art and science of patch testing. Indian J Dermatol Venereol Leprol 2007; 73:289.
  16. Hannuksela M, Salo H. The repeated open application test (ROAT). Contact Dermatitis 1986; 14:221.
  17. Villarama CD, Maibach HI. Correlations of patch test reactivity and the repeated open application test (ROAT)/provocative use test (PUT). Food Chem Toxicol 2004; 42:1719.
  18. Uter WJ, Geier J, Schnuch A. Good clinical practice in patch testing: readings beyond day 2 are necessary: a confirmatory analysis. Members of the Information Network of Departments of Dermatology. Am J Contact Dermat 1996; 7:231.
  19. Todd DJ, Handley J, Metwali M, et al. Day 4 is better than day 3 for a single patch test reading. Contact Dermatitis 1996; 34:402.
  20. Jonker MJ, Bruynzeel DP. The outcome of an additional patch-test reading on days 6 or 7. Contact Dermatitis 2000; 42:330.
  21. Wilkinson DS, Fregert S, Magnusson B, et al. Terminology of contact dermatitis. Acta Derm Venereol 1970; 50:287.
  22. Foussereau J, Benezra C, Maibach HI. Occupational contact dermatitis. Clinical and chemical aspects, Munksgaard, Copenhagen 1982. Vol 26.
  23. Lachapelle JM. A proposed relevance scoring system for positive allergic patch test reactions: practical implications and limitations. Contact Dermatitis 1997; 36:39.
  24. Marks JG, Belsito DV, DeLeo VA, et al. North American Contact Dermatitis Group patch test results for the detection of delayed-type hypersensitivity to topical allergens. J Am Acad Dermatol 1998; 38:911.
  25. Jacob SE, Brod B, Crawford GH. Clinically relevant patch test reactions in children--a United States based study. Pediatr Dermatol 2008; 25:520.
  26. Jensen CD, Paulsen E, Andersen KE. Retrospective evaluation of the consequence of alleged patch test sensitization. Contact Dermatitis 2006; 55:30.
  27. Thyssen JP, Menné T, Nielsen NH, Linneberg A. Is there a risk of active sensitization to PPD by patch testing the general population? Contact Dermatitis 2007; 57:133.
  28. Uter W, Hillen U, Geier J, et al. Is incident sensitization to p-phenylenediamine related to particular exposure patterns? Results of a questionnaire study. Contact Dermatitis 2007; 56:266.
  29. Devos SA, Van Der Valk PG. The risk of active sensitization to PPD. Contact Dermatitis 2001; 44:273.
  30. Dawe SA, White IR, Rycroft RJ, et al. Active sensitization to para-phenylenediamine and its relevance: a 10-year review. Contact Dermatitis 2004; 51:96.
  31. Mitchell JC. The angry back syndrome: eczema creates eczema. Contact Dermatitis 1975; 1:193.
  32. Duarte I, Lazzarini R. Excited skin syndrome associated with patch-test application technique. Dermatitis 2006; 17:161.